Recently presented at the 2021 American Society of Clinical Oncology (ASCO) meeting, a phase II study (NCT04287868) in advanced HPV-positive cancers investigated triplet therapy consisting of: PDS0101 (a liposomal multipeptide therapeutic vaccine targeting HPV16 E6/E7) with M9241 (a tumor-targeting immunocytokine composed of IL-12 heterodimers fused to a monoclonal antibody targeting free DNA in necrotic tumor areas) and M7824 (or bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1). Here, TGFB1 is linked to neoplasm.